Additionally, demonstrating the capacity of CLOCK to specifically and directly regulate chemokines, such as OLFML3, novel chemokine recruiting immune-suppressive microglia into the tumor microenvironment, which in turn recruits microglia into the GBM, encourages the design of clinical trials targeting OLFML3 in high CLOCK GBM patients and abundant microglia [62]. The gene discussed is OLFML3; the disease is neoplasm.